“Maybe the interim analysis of the mild-to-moderate that NP has been talking about?”

My hope is that they won’t conduct an interim analysis of the mild/moderate trial as it wasn’t written into the trial design like the severe trial. The mild/moderate trial is close to being fully enrolled so I don’t see the benefit of doing so as even if it’s good, the FDA is still going to want full trial data.